SARS
MCID: SVR001
MIFTS: 56

Severe Acute Respiratory Syndrome (SARS)

Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Severe Acute Respiratory Syndrome

MalaCards integrated aliases for Severe Acute Respiratory Syndrome:

Name: Severe Acute Respiratory Syndrome 12 75 53 3 44 15 17 72
Sars 12 53 3
Sars-Cov Infection 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2945
ICD9CM 35 079.82
MeSH 44 D045169
NCIt 50 C85064
ICD10 33 J12.81 U04 U04.9
UMLS 72 C1175175

Summaries for Severe Acute Respiratory Syndrome

CDC : 3 Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. The illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained. Since 2004, there have not been any known cases of SARS reported anywhere in the world. The content in this website was developed for the 2003 SARS epidemic. But some guidelines are still being used. Any new SARS updates will be posted on this website.

MalaCards based summary : Severe Acute Respiratory Syndrome, also known as sars, is related to idiopathic interstitial pneumonia and avian influenza, and has symptoms including fever, headache and dry cough. An important gene associated with Severe Acute Respiratory Syndrome is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Ziprasidone and Liraglutide have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related phenotype is immune system.

Disease Ontology : 12 A viral infectious disease that results in infection located in respiratory tract, has material basis in SARS coronavirus (SARS-CoV), which is transmitted by droplet spread of respiratory secretions, transmitted by ingestion of contaminated food, or transmitted by fomites. The infection has symptom fever, has symptom headache, has symptom body aches, has symptom dry cough, and has symptom hypoxia.

Wikipedia : 75 Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the... more...

Related Diseases for Severe Acute Respiratory Syndrome

Diseases in the Respiratory Failure family:

Severe Acute Respiratory Syndrome

Diseases related to Severe Acute Respiratory Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 idiopathic interstitial pneumonia 31.0 IFNG CXCL8 CCL2
2 avian influenza 30.8 TNF CXCL8 CXCL10
3 gastroenteritis 30.4 TNF IFNA1 CXCL8
4 west nile virus 30.4 IRF3 IFNA1 CLEC4M CD209
5 allergic contact dermatitis 30.3 TNF IFNG CXCL8
6 contact dermatitis 30.3 TNF IFNG CXCL8
7 bronchiolitis obliterans 30.1 TNF IFNG CXCL8
8 herpes simplex 30.1 IRF3 IFNB1 IFNA1 CD209
9 measles 30.1 IFNG IFNB1 IFNA1 CD209
10 bronchiolitis 30.0 TNF IFNG CXCL8 CCL5
11 chlamydia 30.0 TNF IFNG CXCL8
12 lung disease 30.0 TNF CXCL8 CXCL10 CCL5 CCL2
13 chagas disease 30.0 TNF IFNG CXCL8 CCL2
14 newcastle disease 30.0 IRF3 IFNB1 IFNA1
15 aspergillosis 30.0 TNF IFNG CD209
16 peritonitis 30.0 TNF CXCL8 CCL2
17 acquired immunodeficiency syndrome 30.0 TNF IFNG IFNA1
18 streptococcal toxic-shock syndrome 29.9 TNF CXCL8
19 dengue disease 29.9 CD40LG CD209 CCL5
20 toxic shock syndrome 29.9 TNF IFNG CXCL8
21 chikungunya 29.9 TNF CCL5 CCL2
22 visceral leishmaniasis 29.8 TNF IFNG CXCL8
23 bacterial infectious disease 29.8 TNF IFNG CXCL8 CCL2
24 trypanosomiasis 29.7 TNF IFNG CXCL8 CCL5 CCL2
25 rabies 29.7 MX1 IRF3 CXCL10 CCL5
26 crohn's colitis 29.7 TNF IFNG CXCL8
27 human immunodeficiency virus infectious disease 29.7 TNF IFNG IFNA1 CCL5
28 tonsillitis 29.6 TNF IFNG CXCL8
29 mycobacterium tuberculosis 1 29.6 TNF IFNG CXCL9 CXCL10 CD209
30 keratoconjunctivitis 29.6 TNF IFNG CXCL8
31 meningitis 29.5 TNF IFNG CXCL8 CCL2
32 vasculitis 29.5 TNF CD40LG CCL2
33 arthritis 29.4 TNF IFNG CXCL8 CCL2
34 encephalitis 29.4 IRF3 CXCL9 CXCL10 CLEC4M CD209 CCL5
35 periodontitis 29.4 TNF IFNG CXCL8 CCL2
36 viral hepatitis 29.4 TNF MX1 IFNA1
37 dermatitis, atopic 29.3 TNF IFNG CXCL8 CCL5
38 pulmonary disease, chronic obstructive 29.3 TNF CXCL8 CXCL10 CCL5 CCL2
39 autoimmune disease 29.2 TNF IFNG IFNA1 CD40LG
40 schistosomiasis 29.2 TNF IFNG CD40LG
41 pneumonia 29.1 TNF CXCL8 CD40LG CCL5 CCL2
42 cytomegalovirus infection 29.0 TNF IRF3 CXCL8 CCL5 CCL2
43 proteasome-associated autoinflammatory syndrome 1 28.9 TNF IFNG CXCL8 CXCL10 CCL5 CCL2
44 viral encephalitis 28.6 TNF MX1 CXCL8 CXCL10 CCL5 CCL2
45 influenza 28.6 TMPRSS2 MX1 IRF3 IFNG IFNB1 IFNA1
46 hepatitis c 28.6 TNF IRF3 IFNG IFNB1 IFNA1 CXCL10
47 human immunodeficiency virus type 1 28.4 TNF IRF3 IFNG IFNA1 CXCL10 CLEC4M
48 myocardial infarction 28.3 TNF CD40LG CCL5 CCL2 ACE2
49 mouth disease 28.0 TNF MX1 IRF3 IFNG IFNA1 CTRL
50 asthma 27.9 TNF IFNG CXCL8 CD40LG CCL5 CCL2

Graphical network of the top 20 diseases related to Severe Acute Respiratory Syndrome:



Diseases related to Severe Acute Respiratory Syndrome

Symptoms & Phenotypes for Severe Acute Respiratory Syndrome

Symptoms:

12
  • fever
  • headache
  • dry cough
  • body aches
  • hypoxia

UMLS symptoms related to Severe Acute Respiratory Syndrome:


fever, pruritus, snoring, coughing

MGI Mouse Phenotypes related to Severe Acute Respiratory Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 ACE2 CCL2 CCL5 CD40LG CLEC4M CXCL10

Drugs & Therapeutics for Severe Acute Respiratory Syndrome

Drugs for Severe Acute Respiratory Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ziprasidone Approved Phase 4 146939-27-7 60854
2
Liraglutide Approved Phase 4 204656-20-2 44147092
3
Glucagon Approved Phase 4 16941-32-5
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
6
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
7 Hypoglycemic Agents Phase 4
8 Quetiapine Fumarate Phase 4 111974-72-2
9 Pharmaceutical Solutions Phase 4
10 Hormones Phase 4
11 Incretins Phase 4
12 Hormone Antagonists Phase 4
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
14 Glucagon-Like Peptide 1 Phase 4
15 Neurotransmitter Agents Phase 4
16 Serotonin Receptor Agonists Phase 4
17 Tranquilizing Agents Phase 4
18 Dopamine Agents Phase 4
19 Serotonin 5-HT2 Receptor Antagonists Phase 4
20 Antidepressive Agents Phase 4
21 Serotonin Antagonists Phase 4
22 Serotonin 5-HT1 Receptor Agonists Phase 4
23 Dopamine agonists Phase 4
24 Central Nervous System Depressants Phase 4
25 Serotonin Agents Phase 4
26 Dopamine Antagonists Phase 4
27 Antipsychotic Agents Phase 4
28 Psychotropic Drugs Phase 4
29 Dopamine D2 Receptor Antagonists Phase 4
30
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
31
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
32
Streptokinase Approved, Investigational Phase 3 9002-01-1
33
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
34 Fibrinolytic Agents Phase 3
35 Anticoagulants Phase 3
36 calcium heparin Phase 3
37 Calcium, Dietary Phase 3
38
Interferon alfacon-1 Approved, Investigational Phase 1, Phase 2 118390-30-0 9554198
39 interferons Phase 2
40 gamma-Globulins Phase 2
41 Antibodies Phase 2
42 Immunoglobulins, Intravenous Phase 2
43 Immunoglobulins Phase 2
44 Rho(D) Immune Globulin Phase 2
45 Interferon-alpha Phase 2
46 Immunoglobulin G Phase 2
47 Anti-Infective Agents Phase 2
48 Antiviral Agents Phase 2
49 Antimetabolites Phase 2
50 Immunologic Factors Phase 2

Interventional clinical trials:

(show all 50)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Lectranal® in Treatment of Seasonal Allergic Rhinitis Symptoms Completed NCT00460538 Phase 4
2 Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II) Completed NCT02305823 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
3 Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up Completed NCT02526030 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
4 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year Completed NCT02534363 Phase 4 Aripiprazole;Quetiapine;Ziprasidone
5 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
6 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
7 Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years Enrolling by invitation NCT03883204 Phase 4 Aripiprazole;Risperidone
8 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up Enrolling by invitation NCT03090503 Phase 4 Aripiprazole;Risperidone
9 Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up Enrolling by invitation NCT02532491 Phase 4 Aripiprazole;Risperidone
10 Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Partially Randomized Controlled Trial Completed NCT03465085 Phase 3 Unfractionated heparin;Streptokinase
11 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
12 A Pilot Study to Evaluate the Safety and Efficacy of IFN-alfacon1 (INFERGEN) in the Treatment of Hospitalized Patients Presenting With Influenza-like Illnesses Due to the Pandemic 2009 Swine Origin Influenza A Virus (S-OIV) H1N1 and Other Circulating Influenza Viruses Unknown status NCT01227798 Phase 1, Phase 2 Interferon alfacon-1;Placebo
13 A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS Completed NCT00215826 Phase 2 Alferon LDO
14 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
15 Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
16 A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Effect of Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease (EViSCO). Recruiting NCT03699904 Phase 2 Valaciclovir;Placebo capsules (containing Avicel blend)
17 Anti-MERS-COV Convalescent Plasma Therapy Withdrawn NCT02190799 Phase 2
18 Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers Completed NCT02670187 Phase 1
19 A Phase I Study of the Safety and Immunogenicity of a SARS Recombinant DNA Plasmid Vaccine, VRC-SRSDNA015-00-VP, in Healthy Adult Volunteers Completed NCT00099463 Phase 1 Vaccine;VRC-SRSDNA015-00-VP
20 A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults Completed NCT03301090 Phase 1
21 A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC Completed NCT00646152 Phase 1 Poly-ICLC
22 A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers Completed NCT01769573 Phase 1 Placebo
23 Phase I, Double-Blinded, Placebo-Controlled, Dose- Escalation Study of the Safety and Immunogenicity of Recombinant SARS-CoV deltaTM S Protein Vaccine Formulated With and Without Alhydrogel® in Healthy Adults When Administered by the Intramuscular Route Withdrawn NCT01376765 Phase 1 Aluminum hydroxide adjuvant (Alhydrogel®)
24 Phase I, Double-Blinded, Placebo-Controlled Dosage Escalation Study of the Safety and Immunogenicity of Adjuvanted and Non-Adjuvanted Inactivated SARS Coronavirus (SARS-CoV) Vaccine Administered by the Intramuscular Route Withdrawn NCT00533741 Phase 1 Aluminum hydroxide;Placebo
25 A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome Unknown status NCT00578825 Lopinavir / Ritonavir plus Ribavirin
26 Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children Unknown status NCT00173563
27 Clinical Study of SARS in Children Completed NCT00173576
28 An Investigation of the Inflammatory Response in Severe Acute Respiratory Syndrome (SARS) Completed NCT00066209
29 Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome Completed NCT00173459
30 Collection of Convalescent SARS Plasma by Apheresis Completed NCT00342524
31 The Physiological Impact of N95 Masks on Medical Staff Completed NCT00173017
32 Testing of Respiratory Specimens for the Validation of the QIAGEN ResPlex II Advanced Panel Test and the Artus Influenza A/B RT-PCR Test Completed NCT01302418
33 Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea, Seoul, Korea Completed NCT01058733
34 Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient Completed NCT02497885
35 A Multicentre, Open Label, Nonrandomised, Non-interventional, Observational, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus: The PREDICTIVE™ Study: Predictable Results and Experience in Diabetes Through Intensification and Control to Target: an International Variability Evaluation Completed NCT00659295 insulin detemir
36 VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases Completed NCT00068926
37 A Multi-centre, International 14-day Inception Cohort Study of Severe Acute Respiratory Infections on the Intensive Care Unit Completed NCT01936207
38 An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses Completed NCT01056354
39 SafeBoosC - Safeguarding the Brain of Our Smallest Children - an Investigator-initiated Randomised, Blinded, Multinational, Phase II Feasibility Clinical Trial on Near-infrared Spectroscopy Monitoring Combined With Defined Treatment Guidelines Versus Standard Monitoring and Treatment as Usual in Premature Infants Completed NCT01590316
40 The 15-year Impact of Severe Acute Respiratory Syndrome on Organ Functions, Exercise Capacity, and Quality of Life in Survivors. Recruiting NCT03443102
41 Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases Recruiting NCT01200953
42 A Prospective Study to Detect Novel Pathogens and Characterize Emerging Infections Recruiting NCT01979705
43 An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses Recruiting NCT01056185
44 The Effectiveness of an Empirical Chinese Medicine Formulation for Idiopathic Pulmonary Fibrosis: an Open Label Clinical Trial Recruiting NCT03274544
45 Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure Recruiting NCT03225807
46 A Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit Recruiting NCT02738645
47 Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases Enrolling by invitation NCT02338986
48 The Interaction Between Severe Acute Respiratory Distress Syndrome Viral Proteins and Monocytes Withdrawn NCT00172263
49 Immune Responses, Transmission and Nucleotide Polymorphisms in Families With SARS Virus Infections Withdrawn NCT00523276
50 Clinical Evaluation and Management of Persons With Severe Acute Respiratory Syndrome (SARS) Withdrawn NCT00073086

Search NIH Clinical Center for Severe Acute Respiratory Syndrome

Cochrane evidence based reviews: severe acute respiratory syndrome

Genetic Tests for Severe Acute Respiratory Syndrome

Anatomical Context for Severe Acute Respiratory Syndrome

MalaCards organs/tissues related to Severe Acute Respiratory Syndrome:

41
Lung, Testes, T Cells, Brain, Liver, Skin, Monocytes

The Foundational Model of Anatomy Ontology organs/tissues related to Severe Acute Respiratory Syndrome:

19
Respiratory Tract

Publications for Severe Acute Respiratory Syndrome

Articles related to Severe Acute Respiratory Syndrome:

(show top 50) (show all 8735)
# Title Authors PMID Year
1
Injury-related hospital admission of female firefighters in South Korea. 38
29214900 2019
2
Synthesis and biological evaluation of novel N9-heterobivalent β-carbolines as angiogenesis inhibitors. 38
30734606 2019
3
Computational evaluation of the reactivity and pharmaceutical potential of an organic amine: A DFT, molecular dynamics simulations and molecular docking approach. 38
31176999 2019
4
TEX264 is a major receptor for mammalian reticulophagy. 38
31362563 2019
5
Design of novel multi-epitope vaccines against severe acute respiratory syndrome validated through multistage molecular interaction and dynamics. 38
30457455 2019
6
Exploitation of glycosylation in enveloped virus pathobiology. 38
31121217 2019
7
Severe acute respiratory syndrome coronavirus spike protein counteracts BST2-mediated restriction of virus-like particle release. 38
31199522 2019
8
Design, synthesis and evaluation of biphenyl imidazole analogues as potent antifungal agents. 38
31358467 2019
9
Evaluating the commercial airliner cabin environment with different air distribution systems. 38
31172603 2019
10
Functional recovery of daily living and sports activities after cosmetic bilateral tibia lengthening. 38
30311058 2019
11
Natural product derived promising anti-MRSA drug leads: A review. 38
31324564 2019
12
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. 38
31233808 2019
13
Design, synthesis and biological evaluation of novel thieno[3,2-d]pyrimidine and quinazoline derivatives as potent antitumor agents. 38
31280016 2019
14
Molecular evidence for the retention of the Thaumatopsyllidae in the order Cyclopoida (Copepoda) and establishment of four suborders and two families within the Cyclopoida. 38
31125659 2019
15
Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). 38
31233865 2019
16
[Anno 1529 - the "English Sweating Sickness" in Vienna, the Turkish troops around Vienna]. 38
31385101 2019
17
Germacrane Sesquiterpenoids as a New Type of Anticardiac Fibrosis Agents Targeting Transforming Growth Factor β Type I Receptor (TβRI). 38
31408333 2019
18
Polybenzyls from Gastrodia elata, their agonistic effects on melatonin receptors and structure-activity relationships. 38
31204226 2019
19
Introducing a new category of activity cliffs with chemical modifications at multiple sites and rationalizing contributions of individual substitutions. 38
31272836 2019
20
Synthesis and biological evaluation of dihydroquinazoline-2-amines as potent non-nucleoside reverse transcriptase inhibitors of wild-type and mutant HIV-1 strains. 38
31091477 2019
21
Novel resveratrol-based flavonol derivatives: Synthesis and anti-inflammatory activity in vitro and in vivo. 38
31077997 2019
22
Polymeric Reactor for the Synthesis of Superparamagnetic-Thermal Treatment of Breast Cancer. 38
31291120 2019
23
Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. 38
31434039 2019
24
Staphylococcus aureus responds to allicin by global S-thioallylation - Role of the Brx/BSH/YpdA pathway and the disulfide reductase MerA to overcome allicin stress. 38
31121222 2019
25
Severe acute respiratory syndrome coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC. 38
31034780 2019
26
Complete genome analysis of a SARS-like bat coronavirus identified in the Republic of Korea. 38
31076983 2019
27
Novel therapies for glaucoma: a patent review (2013-2019). 38
31385719 2019
28
Comparison of adverse events between cluster and conventional immunotherapy for allergic rhinitis patients with or without asthma: A systematic review and meta-analysis. 38
31422860 2019
29
Detection and characterization of a novel bat-borne coronavirus in Singapore using multiple molecular approaches. 38
31418677 2019
30
Dehydrodieugenol B derivatives as antiparasitic agents: Synthesis and biological activity against Trypanosoma cruzi. 38
31103897 2019
31
The effects of past SARS experience and proximity on declines in numbers of travelers to the Republic of Korea during the 2015 MERS outbreak: A retrospective study. 38
31102656 2019
32
Bonding of different self-adhesive resins to high-strength composite resin block treated with surface conditioning. 38
30792147 2019
33
On piecewise models and species-area patterns. 38
31380094 2019
34
Dose distribution prediction in isodose feature-preserving voxelization domain using deep convolutional neural network. 38
31112305 2019
35
Cytokines and related molecules, and adverse reactions related to platelet concentrate transfusions. 38
31327557 2019
36
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. 38
30974127 2019
37
Euphonoids A-G, cytotoxic diterpenoids from Euphorbia fischeriana. 38
31325614 2019
38
The identification of naturally occurring labdane diterpenoid calcaratarin D as a potential anti-inflammatory agent. 38
31022551 2019
39
Advantages of fluid and white matter suppression (FLAWS) with MP2RAGE compared with double inversion recovery turbo spin echo (DIR-TSE) at 7T. 38
31153559 2019
40
Synthesis of N-Substituted Benzamide Derivatives and their Evaluation as Antitumor Agents. 38
31309896 2019
41
A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins. 38
31017815 2019
42
Optimization of pyrrolo[3,4-f]indole-5,7-dione and indole-5,6-dicarbonitrile derivatives as inhibitors of monoamine oxidase. 38
31348537 2019
43
Structure-aided optimization of 3-O-β-chacotriosyl ursolic acid as novel H5N1 entry inhibitors with high selective index. 38
31350154 2019
44
Design, synthesis and anti-inflammatory evaluation of novel pyrrolo[2,3-d]pyrimidin derivatives as potent JAK inhibitors. 38
31378597 2019
45
Design, synthesis and biological evaluation of novel perimidine o-quinone derivatives as non-intercalative topoisomerase II catalytic inhibitors. 38
31377387 2019
46
Novel approaches to the discovery of selective human monoamine oxidase-B inhibitors: is there room for improvement? 38
31268358 2019
47
Synthesis of novel andrographolide beckmann rearrangement derivatives and evaluation of their HK2-related anti-inflammatory activities. 38
31009914 2019
48
Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications. 38
31035237 2019
49
Fitness barriers limit reversion of a proofreading-deficient coronavirus. 38
31341046 2019
50
A systematic risk-based strategy to select personal protective equipment for infectious diseases. 38
31358421 2019

Variations for Severe Acute Respiratory Syndrome

Expression for Severe Acute Respiratory Syndrome

Search GEO for disease gene expression data for Severe Acute Respiratory Syndrome.

Pathways for Severe Acute Respiratory Syndrome

Pathways related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 TNF MX1 IRF3 IFNG IFNB1 IFNA1
2
Show member pathways
13.67 TNF IFNG IFNB1 IFNA1 CXCL9 CXCL8
3
Show member pathways
13.37 TNF CXCL9 CXCL8 CXCL10 CD40LG CCL5
4
Show member pathways
13.27 TNF CXCL9 CXCL8 CXCL10 CD40LG CCL5
5
Show member pathways
13.22 TNF MX1 IRF3 IFNG IFNB1 IFNA1
6
Show member pathways
12.97 TNF IRF3 IFNB1 IFNA1 CXCL8 CCL5
7
Show member pathways
12.89 TNF IFNG IFNA1 CXCL9 CXCL8 CTSL
8
Show member pathways
12.84 CXCL9 CXCL8 CXCL10 CCL5 CCL2
9
Show member pathways
12.72 TNF IRF3 IFNG IFNB1 IFNA1 CXCL8
10
Show member pathways
12.59 TNF IRF3 IFNG IFNB1 IFNA1 CXCL9
11
Show member pathways
12.54 MX1 IRF3 IFNG IFNB1 IFNA1
12
Show member pathways
12.47 TNF IFNG IFNB1 IFNA1
13
Show member pathways
12.35 TNF IFNG CXCL8 CXCL10 CCL2
14
Show member pathways
12.3 TNF IFNG CCL5 CCL2
15
Show member pathways
12.29 CXCL9 CXCL8 CXCL10 CCL5 CCL2
16
Show member pathways
12.27 TNF IRF3 IFNG CXCL8
17 12.27 TNF IRF3 IFNG IFNA1 CXCL10 CD40LG
18
Show member pathways
12.26 TNF MX1 IRF3 IFNG IFNB1 IFNA1
19
Show member pathways
12.25 TNF IRF3 IFNB1 CXCL8
20 12.22 TNF IFNG IFNB1 IFNA1 CLEC4M CD209
21
Show member pathways
12.2 TNF IFNG IFNB1 IFNA1
22
Show member pathways
12.18 CXCL9 CXCL8 CXCL10 CCL5 CCL2
23
Show member pathways
12.17 TNF IFNG IFNB1 CXCL8 CXCL10 CTSL
24 12.09 TNF IFNG CTSL CCL2
25 12.04 TNF IFNG CXCL8 CXCL10 CCL2
26 11.98 TNF IFNB1 CXCL10 CCL5 CCL2
27 11.95 TNF IFNG CD209
28 11.94 TNF CXCL8 CCL2
29 11.9 IFNG IFNB1 CXCL8
30 11.87 TNF CXCL8 CCL2
31 11.87 TNF IFNG CXCL8
32 11.87 TNF CXCL8 CD40LG
33
Show member pathways
11.8 TNF IFNG CXCL8 CD40LG
34 11.78 TNF IFNG IFNB1 CD209
35 11.77 TNF IFNG CXCL8 CTSL CCL5 CCL2
36 11.73 TNF IRF3 CXCL8
37
Show member pathways
11.7 TNF IFNG CXCL8 CD40LG
38 11.69 TNF CXCL8 CCL5 CCL2
39 11.52 TNF IFNG CXCL8 CD40LG CCL2
40 11.51 TNF IFNG CCL2
41 11.49 TNF CXCL8 CXCL10 CCL5 CCL2
42 11.42 IFNG IFNB1 CXCL9 CXCL10
43 11.32 CD40LG CCL2 ACE2
44 11.28 TNF IFNG IFNB1
45 11.21 TNF IFNB1 CXCL8 CCL5
46 11.03 TNF CXCL9 CXCL8 CXCL10 CD40LG CCL5
47 11.02 TNF CXCL9 CXCL8 CXCL10 CD40LG CCL5
48 10.95 TNF IFNG CXCL9 CXCL10 CCL5 CCL2
49 10.9 TNF CCL2

GO Terms for Severe Acute Respiratory Syndrome

Cellular components related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 TNF IFNG IFNB1 IFNA1 CXCL9 CXCL8
2 external side of plasma membrane GO:0009897 9.55 TNF CXCL9 CXCL10 CD40LG CD209
3 extracellular region GO:0005576 9.5 TNF TMPRSS2 IFNG IFNB1 IFNA1 CXCL9
4 host cell GO:0043657 9.26 CLEC4M CD209

Biological processes related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 TNF IFNG CXCL9 CXCL8 CXCL10 CD40LG
2 regulation of cell proliferation GO:0042127 9.96 TNF CXCL9 CXCL10 ACE2
3 chemotaxis GO:0006935 9.95 CXCL9 CXCL8 CXCL10 CCL5 CCL2
4 response to bacterium GO:0009617 9.91 IRF3 CXCL9 CXCL10 CCL2
5 cellular response to lipopolysaccharide GO:0071222 9.88 TNF IRF3 CXCL9 CXCL8 CXCL10 CCL2
6 viral entry into host cell GO:0046718 9.87 CLEC4M CD209 ACE2
7 cell chemotaxis GO:0060326 9.87 CXCL10 CCL5 CCL2
8 cytokine-mediated signaling pathway GO:0019221 9.87 TNF IFNB1 IFNA1 CXCL8 CXCL10 CCL5
9 cellular response to interleukin-1 GO:0071347 9.86 CXCL8 CCL5 CCL2
10 B cell differentiation GO:0030183 9.86 IFNB1 IFNA1 CD40LG
11 type I interferon signaling pathway GO:0060337 9.86 MX1 IRF3 IFNB1 IFNA1
12 cellular response to organic cyclic compound GO:0071407 9.85 TNF CCL5 CCL2
13 regulation of insulin secretion GO:0050796 9.85 TNF IFNG CCL5
14 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.85 CXCL9 CXCL8 CXCL10
15 neutrophil chemotaxis GO:0030593 9.85 CXCL9 CXCL8 CXCL10 CCL5 CCL2
16 positive regulation of T cell proliferation GO:0042102 9.84 CD40LG CD209 CCL5
17 negative regulation of viral genome replication GO:0045071 9.83 TNF MX1 IFNB1 CCL5
18 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL9 CXCL8 CXCL10 CCL5 CCL2
19 antigen processing and presentation GO:0019882 9.82 CTSL CLEC4M CD209
20 protein kinase B signaling GO:0043491 9.82 TNF CCL5 CCL2
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.81 TNF IRF3 CCL5 CCL2
22 response to exogenous dsRNA GO:0043330 9.8 IRF3 IFNB1 IFNA1
23 leukocyte cell-cell adhesion GO:0007159 9.8 CLEC4M CD40LG CD209 CCL5
24 B cell proliferation GO:0042100 9.79 IFNB1 IFNA1 CD40LG
25 cellular response to fibroblast growth factor stimulus GO:0044344 9.79 CXCL8 CCL5 CCL2
26 leukocyte chemotaxis GO:0030595 9.76 CXCL9 CXCL8 CXCL10
27 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.75 IFNG IFNB1 IFNA1
28 viral genome replication GO:0019079 9.74 CLEC4M CD209 CCL2
29 positive regulation of T cell migration GO:2000406 9.71 CXCL10 CCL5
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IFNG
31 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.71 CXCL8 CCL5
32 macrophage chemotaxis GO:0048246 9.7 CCL5 CCL2
33 PERK-mediated unfolded protein response GO:0036499 9.7 CXCL8 CCL2
34 neutrophil activation GO:0042119 9.69 CXCL8 CCL5
35 intracellular transport of virus GO:0075733 9.69 CLEC4M CD209
36 modulation by virus of host morphology or physiology GO:0019048 9.67 CLEC4M CD209
37 cell-cell recognition GO:0009988 9.66 CLEC4M CD209
38 virion attachment to host cell GO:0019062 9.65 CLEC4M CD209
39 regulation of immunoglobulin secretion GO:0051023 9.65 TNF CD40LG
40 humoral immune response GO:0006959 9.65 TNF IFNG IFNB1 IFNA1 CCL2
41 receptor biosynthetic process GO:0032800 9.64 TNF ACE2
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.63 TNF IFNG
43 peptide antigen transport GO:0046968 9.63 CLEC4M CD209
44 response to virus GO:0009615 9.63 TNF MX1 IFNG IFNB1 CXCL10 CCL5
45 positive regulation of vitamin D biosynthetic process GO:0060557 9.6 TNF IFNG
46 macrophage apoptotic process GO:0071888 9.59 IRF3 CTSL
47 defense response to virus GO:0051607 9.5 MX1 IRF3 IFNG IFNB1 IFNA1 CXCL9
48 defense response GO:0006952 9.17 TNF MX1 IFNB1 IFNA1 CXCL9 CXCL8
49 inflammatory response GO:0006954 10.02 TNF CXCL9 CXCL8 CXCL10 CD40LG CCL5
50 adaptive immune response GO:0002250 10.01 IFNG IFNB1 IFNA1 CTSL CLEC4M CD209

Molecular functions related to Severe Acute Respiratory Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.43 CLEC4M CD209 ACE2
2 type I interferon receptor binding GO:0005132 9.37 IFNB1 IFNA1
3 chemokine activity GO:0008009 9.35 CXCL9 CXCL8 CXCL10 CCL5 CCL2
4 virion binding GO:0046790 9.32 CLEC4M CD209
5 cytokine activity GO:0005125 9.32 TNF IFNG IFNB1 IFNA1 CXCL9 CXCL8
6 CXCR3 chemokine receptor binding GO:0048248 9.16 CXCL9 CXCL10

Sources for Severe Acute Respiratory Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....